Abstract 93P
Background
Bevacizumab (BV) or Ramucirumab (RAM) combining with FOLFIRI (infusional 5-fluorouracil, leucovorin and irinotecan) improves progression-free survival (PFS) and overall survival (OS) in second-line chemotherapy for patients with metastatic colorectal cancer (mCRC). However, no direct comparison has been conducted in phase III study. The aim of this study is to compare the results of FOLFIRI+BV and FOLFIRI+RAM in second-line chemotherapy for mCRC.
Methods
We retrospectively identified 95 Patients who received either FOLFIRI+BV (n = 49) or FOLFIRI+ RAM (n = 46) as second-line chemotherapy after progression during fluoropyrimidine plus oxaliplatin, from 2016 to 2023 at Nagoya City University Hospital. Clinical outcomes were compared between the two groups.
Results
Baseline characteristics were well balanced between the two groups. BV was previously administrated to 32 patients (65%) in FOLFIRI+BV and 32 patients (70%) in FOLFIRI+RAM. No significant differences were found for PFS of first-line chemotherapy between the two groups. Median PFS was 5.6 months in FOLFIRI+BV and 6.2 months in FOLFIRI+RAM, with an HR of 1.44 [95% CI, 0.90-2.30]. Median survival time after initiation of second-line chemotherapy was 18.7 months in FOLFIRI+BV and 15.3 months in FOLFIRI+RAM with an HR of 1.25 [95% CI, 0.74-2.14]. Overall response rate and disease control rate were 6.7% and 73.3% in FOLFIRI+BV, and 17.1% and 75.6% in FOLFIRI+RAM. The frequency of hypertension and proteinuria grade 3 was 0% and 2% in FOLFIRI+BV, but 13% and 13% in FOLFIRI+RAM.
Conclusions
FOLFIRI+BV and FOLFIRI+RAM showed similar anti-tumor activity in second-line treatment for mCRC although RAM may be related to incidence of hypertension and proteinuria.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.